(Q45213264)

10 December 2017

title

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer (English)

1 reference

10 December 2017

0 references

Veronique M Neumeister

1

1 reference

10 December 2017

Catherine A Sullivan

2

1 reference

10 December 2017

Robert Lindner

3

1 reference

10 December 2017

Kimberley Lezon-Geyda

4

1 reference

10 December 2017

Jia Li

5

1 reference

10 December 2017

Jan Zavada

6

1 reference

10 December 2017

Maritza Martel

7

1 reference

10 December 2017

Peter M Glazer

8

1 reference

10 December 2017

David P Tuck

9

1 reference

10 December 2017

David L Rimm

10

1 reference

10 December 2017

Lyndsay Harris

11

1 reference

10 December 2017

language of work or name

English

0 references

publication date

14 September 2012

1 reference

Breast Cancer Research and Treatment

10 December 2017

published in

1 reference

10 December 2017

volume

136

1 reference

10 December 2017

issue

1

1 reference

10 December 2017

page(s)

67-75

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Cancer susceptibility and the functions of BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

The role of hypoxia-inducible factors in tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Immunohistochemical detection of changes in tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Automated subcellular localization and quantification of protein expression in tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Expression of BRCA1 protein in breast cancer and its prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

BRCA1 gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

PARP inhibitor treatment in ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2232-0

10.1007/S10549-012-2232-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

1033045079

0 references

1 reference